Brad Evans

Brad Evans, is Senior Scientific Advisor for Disease State at BioIVT, where he leads scientific strategy around the use of high-quality biospecimens to accelerate biomarker-driven research and precision medicine. He brings more than 20 years of translational science experience across academia, biotech, and large pharma, with expertise spanning oncology, immunology, and infectious diseases.

Brad has held scientific leadership roles at Merck Research Laboratories, Bayer Healthcare Pharmaceuticals, and NomoCan Pharmaceuticals, where he patented a first-in-class immuno-oncology therapeutic. His expertise includes multi-omic biomarker development, patient-centric sample collection methodologies, and automation in translational research. He has extensive experience designing and executing preclinical and clinical studies, supporting regulatory submissions, and developing companion diagnostics.

At BioIVT, Brad partners with clients to integrate biospecimens into discovery and clinical workflows, enabling robust biomarker discovery, validation, and application in drug development. He has authored and contributed to numerous scientific publications and has been an invited speaker at international conferences on translational medicine, biomarkers, and precision oncology.